1. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
   Christophe Bontoux et al, 2022, Cancers CrossRef
2. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
   Yingjia Sun et al, 2022, Journal of Clinical Medicine CrossRef
3. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
   Mo Shen et al, 2022, Frontiers in Oncology CrossRef
4. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer
   Pei-Shan Hung et al, 2020, Cancers CrossRef
5. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013–2018)
   Noémie Letellier et al, 2022, International Journal of Environmental Research and Public Health CrossRef
6. The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
   Yan Liu et al, 2021, Cancer Management and Research CrossRef
7. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China
   Yongchun Zhou et al, 2021, Frontiers in Oncology CrossRef
8. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
   Firas Batrash et al, 2023, Experimental Hematology & Oncology CrossRef
9. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
   Liyuan Gao et al, 2022, Frontiers in Genetics CrossRef